[CAS NO. 69207-52-9] McN3716
PRODUCTS SPECIFICATIONS [69207-52-9]
DESCRIPTION [69207-52-9]
Overview
| MDL | MFCD00865479 |
|---|---|
| Molecular Weight | 298.46 |
| Molecular Formula | C18H34O3 |
| SMILES | O=C(C1(CCCCCCCCCCCCCC)OC1)OC |
Summary
McN3716 is a carnitine palmitoyltransferase I ( CPT-1 ) inhibitor.
IC50 & Target
Carnitine palmitoyltransferase I (CPT-1) [1]
In Vivo
Inhibition of brain mitochondrial β-oxidation by McN3716 (Methyl palmoxirate, MEP) significantly reduces the levels of all measured HETE and epoxytrienoic acids (EET), nonenzymatic auto-oxidative metabolites of ARA, by 23% to 44% and 32% to 50% compared with vehicle-injected rats, respectively, except for 15-HETE which was unaffected. There is a significant 34% reduction in the level of 6-keto-PGF 1α , a byproduct of PGI 2 (prostacyclin) in McN3716-treated rats. Similarly, the brain level of hydroxyeicosapentaenoic acids, nonenzymatic auto-oxidative metabolites of EPA, is reduced by 35% to 76% upon McN3716 treatment relative to vehicle [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Synonyms